Evaluation of integrated interventions layered on mass drug administration for urogenital schistosomiasis elimination: a cluster-randomised trial.


Journal

The Lancet. Global health
ISSN: 2214-109X
Titre abrégé: Lancet Glob Health
Pays: England
ID NLM: 101613665

Informations de publication

Date de publication:
08 2019
Historique:
received: 07 11 2018
revised: 25 03 2019
accepted: 02 04 2019
pubmed: 1 7 2019
medline: 23 5 2020
entrez: 1 7 2019
Statut: ppublish

Résumé

Elimination of schistosomiasis as a public health problem and interruption of transmission in selected areas are targets set by WHO for 2025. Our aim was to assess biannual mass drug administration (MDA) applied alone or with complementary snail control or behaviour change interventions for the reduction of Schistosoma haematobium prevalence and infection intensity in children from Zanzibar and to compare the effect between the clusters. In a 5-year repeated cross-sectional cluster-randomised trial, 90 shehias (small administrative regions; clusters) in Zanzibar eligible owing to available natural open freshwater bodies and public primary schools were randomly allocated (ratio 1:1:1) to receive one of three interventions: biannual MDA with praziquantel alone (arm 1) or in combination with snail control (arm 2), or behaviour change activities (arm 3). Neither participants nor field or laboratory personnel were blinded to the intervention arms. From 2012 to 2017, annually, a single urine sample was collected from approximately 100 children aged 9-12 years in the main public primary school of each shehia. The primary outcome was S haematobium infection prevalence and intensity in 9-12-year-old children after 5 years of follow-up. This study is completed and was registered with the ISRCTN, number 48837681. The trial was done from Nov 1, 2011, through to Dec 31, 2017 and recruitment took place from Nov 2, 2011, until May 17, 2017. At baseline we enrolled 8278 participants, of whom 2899 (35%) were randomly allocated to arm 1, 2741 (33%) to arm 2, and 2638 (32%) to arm 3. 120 (4·2%) of 2853 in arm 1, 209 (7·8%) of 2688 in arm 2, and 167 (6·4%) of 2613 in arm 3 had S haematobium infections at baseline. Heavy infections (≥50 eggs per 10 mL of urine) were found in 126 (1·6%) of 8073 children at baseline. At the 5-year endline survey, 46 (1·4%) of 3184 in arm 1, 56 (1·7%) of 3217 (odds ratio [OR] 1·2 [95% CI 0·6-2·7] vs arm 1) in arm 2, and 58 (1·9%) of 3080 (1·3 [0·6-2·9]) in arm 3 had S haematobium infections. Heavy infections were detected in 33 (0·3%) of 9462 children. Biannual MDA substantially reduced the S haematobium prevalence and infection intensity but was insufficient to interrupt transmission. Although snail control or behaviour change activities did not significantly boost the effect of MDA in our study, they might enhance interruption of transmission when tailored to focal endemicity and applied for a longer period. It is now necessary to focus on reducing prevalence in remaining hotspot areas and to introduce new methods of surveillance and public health response so that the important gains can be maintained and advanced. University of Georgia Research Foundation Inc and Bill & Melinda Gates Foundation.

Sections du résumé

BACKGROUND
Elimination of schistosomiasis as a public health problem and interruption of transmission in selected areas are targets set by WHO for 2025. Our aim was to assess biannual mass drug administration (MDA) applied alone or with complementary snail control or behaviour change interventions for the reduction of Schistosoma haematobium prevalence and infection intensity in children from Zanzibar and to compare the effect between the clusters.
METHODS
In a 5-year repeated cross-sectional cluster-randomised trial, 90 shehias (small administrative regions; clusters) in Zanzibar eligible owing to available natural open freshwater bodies and public primary schools were randomly allocated (ratio 1:1:1) to receive one of three interventions: biannual MDA with praziquantel alone (arm 1) or in combination with snail control (arm 2), or behaviour change activities (arm 3). Neither participants nor field or laboratory personnel were blinded to the intervention arms. From 2012 to 2017, annually, a single urine sample was collected from approximately 100 children aged 9-12 years in the main public primary school of each shehia. The primary outcome was S haematobium infection prevalence and intensity in 9-12-year-old children after 5 years of follow-up. This study is completed and was registered with the ISRCTN, number 48837681.
FINDINGS
The trial was done from Nov 1, 2011, through to Dec 31, 2017 and recruitment took place from Nov 2, 2011, until May 17, 2017. At baseline we enrolled 8278 participants, of whom 2899 (35%) were randomly allocated to arm 1, 2741 (33%) to arm 2, and 2638 (32%) to arm 3. 120 (4·2%) of 2853 in arm 1, 209 (7·8%) of 2688 in arm 2, and 167 (6·4%) of 2613 in arm 3 had S haematobium infections at baseline. Heavy infections (≥50 eggs per 10 mL of urine) were found in 126 (1·6%) of 8073 children at baseline. At the 5-year endline survey, 46 (1·4%) of 3184 in arm 1, 56 (1·7%) of 3217 (odds ratio [OR] 1·2 [95% CI 0·6-2·7] vs arm 1) in arm 2, and 58 (1·9%) of 3080 (1·3 [0·6-2·9]) in arm 3 had S haematobium infections. Heavy infections were detected in 33 (0·3%) of 9462 children.
INTERPRETATION
Biannual MDA substantially reduced the S haematobium prevalence and infection intensity but was insufficient to interrupt transmission. Although snail control or behaviour change activities did not significantly boost the effect of MDA in our study, they might enhance interruption of transmission when tailored to focal endemicity and applied for a longer period. It is now necessary to focus on reducing prevalence in remaining hotspot areas and to introduce new methods of surveillance and public health response so that the important gains can be maintained and advanced.
FUNDING
University of Georgia Research Foundation Inc and Bill & Melinda Gates Foundation.

Identifiants

pubmed: 31255591
pii: S2214-109X(19)30189-5
doi: 10.1016/S2214-109X(19)30189-5
pmc: PMC6624424
pii:
doi:

Substances chimiques

Anthelmintics 0
Praziquantel 6490C9U457

Types de publication

Journal Article Randomized Controlled Trial Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

e1118-e1129

Commentaires et corrections

Type : CommentIn

Informations de copyright

Copyright © 2019 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license. Published by Elsevier Ltd.. All rights reserved.

Références

Lancet Infect Dis. 2006 Jul;6(7):411-25
pubmed: 16790382
PLoS Clin Trials. 2007 Apr 13;2(4):e18
pubmed: 17443237
Acta Trop. 2008 Jan;105(1):45-54
pubmed: 17996207
N Engl J Med. 2009 Jan 8;360(2):106-9
pubmed: 19129524
Trans R Soc Trop Med Hyg. 2009 Oct;103(10):1031-44
pubmed: 19409588
Acta Trop. 2013 Nov;128(2):423-40
pubmed: 22580511
BMC Public Health. 2012 Oct 30;12:930
pubmed: 23110494
PLoS Negl Trop Dis. 2013 Oct 17;7(10):e2474
pubmed: 24147165
Lancet. 2014 Jun 28;383(9936):2253-64
pubmed: 24698483
Trop Med Parasitol. 1989 Jun;40(2):189-94
pubmed: 2505381
Acta Trop. 2015 Jan;141(Pt B):229-34
pubmed: 25301340
PLoS Negl Trop Dis. 2015 Dec 28;9(12):e0004290
pubmed: 26709922
Parasit Vectors. 2016 Jan 04;9:5
pubmed: 26727915
J Biosoc Sci. 2016 Sep;48 Suppl 1:S56-73
pubmed: 27428066
PLoS Negl Trop Dis. 2016 Jul 21;10(7):e0004794
pubmed: 27441556
Acta Trop. 2016 Nov;163:142-8
pubmed: 27498244
PLoS Negl Trop Dis. 2016 Sep 22;10(9):e0004946
pubmed: 27658198
Lancet Infect Dis. 2017 Feb;17(2):e64-e69
pubmed: 27914852
Int J Infect Dis. 2017 Jan;54:130-137
pubmed: 27939558
Parasit Vectors. 2016 Dec 16;9(1):646
pubmed: 27986092
Parasit Vectors. 2017 Jan 26;10(1):47
pubmed: 28126024
Infect Dis Poverty. 2017 Feb 20;6(1):42
pubmed: 28219412
Infect Dis Poverty. 2017 Mar 22;6(1):63
pubmed: 28327187
Lancet. 2017 Sep 16;390(10100):1260-1344
pubmed: 28919118
J Infect Dis. 2017 Dec 12;216(11):1425-1433
pubmed: 28968877
Am J Trop Med Hyg. 2017 Dec;97(6):1810-1817
pubmed: 29016344
Parasit Vectors. 2018 Oct 23;11(1):552
pubmed: 30352631
PLoS Negl Trop Dis. 2019 May 6;13(5):e0007268
pubmed: 31059495

Auteurs

Stefanie Knopp (S)

Swiss Tropical and Public Health Institute, Basel, Switzerland; University of Basel, Basel, Switzerland; Wolfson Wellcome Biomedical Laboratories, Department of Life Sciences, Natural History Museum, London, UK. Electronic address: s.knopp@swisstph.ch.

Bobbie Person (B)

Schistosomiasis Consortium for Operational Research and Evaluation, University of Georgia, Athens, GA, USA.

Shaali M Ame (SM)

Public Health Laboratory-Ivo de Carneri, Pemba, Tanzania.

Said M Ali (SM)

Public Health Laboratory-Ivo de Carneri, Pemba, Tanzania.

Jan Hattendorf (J)

Swiss Tropical and Public Health Institute, Basel, Switzerland; University of Basel, Basel, Switzerland.

Saleh Juma (S)

Public Health Laboratory-Ivo de Carneri, Pemba, Tanzania.

Juma Muhsin (J)

Neglected Diseases Programme, Ministry of Health, Zanzibar, Tanzania.

Iddi S Khamis (IS)

Neglected Diseases Programme, Ministry of Health, Zanzibar, Tanzania.

Khalfan A Mohammed (KA)

Neglected Diseases Programme, Ministry of Health, Zanzibar, Tanzania.

Jürg Utzinger (J)

Swiss Tropical and Public Health Institute, Basel, Switzerland; University of Basel, Basel, Switzerland.

Elizabeth Hollenberg (E)

Schistosomiasis Control Initiative, Department of Infectious Disease Epidemiology, Faculty of Medicine, Imperial College London, London, UK.

Fatma Kabole (F)

Neglected Diseases Programme, Ministry of Health, Zanzibar, Tanzania.

David Rollinson (D)

Wolfson Wellcome Biomedical Laboratories, Department of Life Sciences, Natural History Museum, London, UK.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH